



RxFiles – Drug Comparison Charts 9th Edition (2012-2013)



CHART PEARLS 9th Edition

Highlights of Just a Few of the Revisions

Guidelines Reviewed & Incorporated into Charts

AAN, AAP, ACR, ADA, AHA, CDA, Chcp, Chest, IDSA, NACI, etc

ANTIPLATELET & ANTITHROMBOTIC CHART pg 10-11

- New layout: greater detail regarding new agents (**ELIQUIS**, **PRADAX**, and **XARELTO**); & consideration of CHEST Guidelines²⁰¹².
- Updated summary of landmark trials: **RELY**, **ROCKET-AF**, **WARIS-II**

ATRIAL FIBRILLATION – New CHART pg 11a-c

- Summary of Atrial Fibrillation Guidelines
- Risk calculator tools: Clots^{CHA2DS2, CHA2DS2VASc} & Bleeds^{HAS-BLED}
- New oral anticoagulants: recommendations & considerations

DIABETES CHARTS

- Saxagliptin added to main section pg 25
- Addition of **ORIGIN** trial summary line pg 30a
- Expanded T2DM overview pg 31

HIRSUTISM, Idiopathic – New CHART pg 36

- Drug Management Algorithm and Chart

New Charts - 10 in all

- Atrial Fibrillation Chart Pg 11 a-c
- Diabetes Trials: Lipid, ASA & BP Pg 30 b
- Diabetes: Approach to T2DM Treatment Pg 30 c
- Hirsutism: Idiopathic Pg 36
- Viral Hepatitis: B & C Pg 57a-d
- Opioids, Pain: Acute vs Palliative vs CNCP Pg 70a-b
- Anticholinergic Drug List Pg 77 a
- Elderly/LTC: Pearls for Prescribing Pg 77 b
- Peri-Pregnancy Pg 91 a,b
- Palliative Care Pg 121 c,d

New Drug (Brand Name) Additions

ABSTRAL, **ACZONE**, **ASMANEX TWISTHALER**, **BANZEL**, **BIANCA**, **BRILINTA**, **BYETTA**, **COMPLERA**, **EDURANT**, **FAMPYRA**, **GELNIQUE**, **JALYN**, **LODALIS**, **LUXIQ**, **NYDA**, **ONBREZ BREEZHALER**, **ONSOLIS**, **RAPAFLO**, **RESOTRAN**, **SAPHRIS**, **SEASONIQUE**, **STAXYN**, **SUBLINOX**, **TACTUO**, **TRAJENTA**, **TWYNSTA**, **ZENHALE** & **ZUACTA**.

Scanning Through The Charts

- **Hypertension** – updated guidelines^{2012 Canadian} pg 6-7
- **Community Acquired Pneumonia** added guidelines pg 62
- **GI Acid Suppression** Recommendations^{American} for prevention of NSAID ulcer complications pg 41
- **NSAID/COXIB**: Systematic review of ↑ CV risk pg 69
- **Opioid Chart**: new fentanyl 12ug patch; **ZYTRAM** pg 70
- **Oral Contraceptive**: **YAZ**, generics & missed pills pg 87
- **OTC**: new cough guidelines; strengthen warning regarding cough/cold products in age <6yrs pg 94, probiotic comments pg 56 & pg 95, updated Vit B₁₂ & calcium info pg 97

By the Numbers

Total pages: **164**. New pages: **20**. New charts: **10**.

Changes: **thousands**. Charts updated **daily**, then to web/apps.

New Pregnancy & Lactation Symbols

See page 2 for the new RxFiles risk categories.

\$ Comparisons^{/30day} that caught our



Proton Pump Inhibitors (PPIs) pg 41

- Rabeprazole **ARIET** 2x10mg od or 20mg od \$23 ⬇
 - Omeprazole **g** 20mg od \$32 ⬇
- (Generic esomeprazole^{\$72}, lansoprazole & pantoprazole^{\$30})

Atypical Antipsychotics – HS, Low Dosing pg 108

- Quetiapine **SEROQUEL** 25-50mg hs \$15-22
- Risperidone **RISPERDAL** 0.5-1mg hs \$20-21
- Olanzapine **ZYPREXA** 2.5-5mg hs \$28-49 ⬇

Substantially **REDUCED** SK Formulary Cost

- Amlodipine generic = **NORVASC** 2.5mg od \$15
- Candesartan generic = **ATACAND** 8mg od \$21
- Clopidogrel generic = **PLAVIX** 75mg od \$37 ⬇
- Entacapone generic = **COMTAN** 200mg tid \$63
- Finasteride generic = **PROSCAR, PROPECIA** 5mg od \$28 ⬇
- Latanoprost generic = **XALATAN** 1gtt hs \$18
- Losartan generic = **COZAAR** 25mg od \$22
- Montelukast generic = **SINGULAIR** 10mg od \$34 ⬇
- Mycophenolate generic = **CELLCEPT** 500mg q12h \$100 ⬇
- Telmisartan generic = **MICARDIS** 80mg od \$21
- Risedronate generic = **ACTONEL** 35mg/wk \$280/y ⬇
- Rivastigmine generic = **EXELON** 3mg bid \$67 ⬇
- Rosuvastatin generic = **CRESTOR** 5-10mg od \$24

Substantially **INCREASED** SK Formulary Cost

- Auranofin **RIDAURA** 3mg po bid \$4,650/y

Status & Reimbursement Changes

- **On SK Formulary**: **LANTUS**, **LEVEMIR**, & **TWYNSTA**
- **New EDS** ⬇: **ABILIFY**, **ACLASTA**, **ACTONEL DR**, **ADCIRCA**, **BANZEL**, **BRILINTA**, **COMPLERA**, **EFFIENT**, **GILENYA**, **INCIVEK**, **INVEGA SUSTENNA**, **JANUMET**, **JANUVIA**, **ONGLYZA**, **OXYNEO**, **PROLIA**, **EDURANT**, **ULORIC**, **VIMPAT**, **VICTRELIS**, & **XARELTO**
- **New generics**^{LS}: Clopidogrel, Finasteride, Latanoprost, Losartan, Meropenem, Montelukast, Mycophenolate, Nabilone, Repaglinide, Rizatriptan, Rosuvastatin, Telmisartan, & Valsartan.
- **New full NIHB** ⬇: Bupropion SR, Cyclobenzaprine, **LEVAQUIN**, **NOVIR** (100mg), **NRT** (Lozenge, Inhaler), **VAGIFEM** (10mcg), **WELLBUTRIN XL**, & **YAZ**.
- **New prior NIHB approval** ⬇: **ABILIFY**, **DARIFENACIN**, **INCIVEK**, **JANUVIA**, **PROLIA**, **SUBOXONE**, **ULORIC**, & **VICTRELIS**.

Outcome Evidence from MAJOR Trials

Major outcome trials & dosages used are often noted on charts when available. Recent: **ACTIVE-A**, **ACTIVE W**, **ARISTOTLE**, **RELY**, **ROCKET-AF**, **Warfasa** (p 11), **HPS** (p 14), **Saturn** (p 15), **AIM-high**, **SHARP** (p 14, 15), **ACCORD-BP**, **JPAD**, **POPADAD** (p 30b) **AZURE** (p 75).

RxFiles Academic Detailing c/o Saskatoon City Hospital, 01 Queen Street, Saskatoon, SK Canada S7K 0M7
TEL: (306) 655-8505 FAX: (306) 655-7980 www.RxFiles.ca

See our website for subscription options on accessing our information online. Saskatchewan health professionals have free automatic access through health regions/universities, or individually through SHIRP.

Recent Adverse Reaction Advisories

Health Canada [Advisories, Warnings and Recalls - Health Canada](#) & FDA

- ACTOS (pioglitazone HCl)**: potential association with bladder cancer
- AVASTIN (bevacizumab)**: higher incidence of new cases of ovarian failure observed in premenopausal women
- BENLYSTA (belimumab)**: hypersensitivity and infusion reactions
- Bisphosphonates**: small but ↑ risk of atypical thigh fractures
- CAPRELSA (vandetanib)**: serious risk of abnormal heart rhythm
- CELEXA (citalopram)**: associated abnormal heart rhythm (QT)
- CIPRALEX (escitalopram)**: associated abnormal heart rhythm (QT)
- Finasteride (PROPECIA, PROSCAR)**: ↑ breast cancer risk in men
- Finasteride and Dutasteride**: may ↑ risk of high-grade prostate ca
- Fluoroquinolone antibiotics**: may ↑ muscle weakness in myasthenia gravis
- Metoclopramide**: ↑ warnings on abnormal muscle movement
- PLAVIX (clopidogrel)**: new recommendations for use with PPIs
- RASILEZ (aliskiren)**: potential risks of CV and renal adverse events in patients with type 2 diabetes
- STRATTERA (atomoxetine)**: association with ↑ BP and heart rate
- SUBLINOX (zolpidem tartrate)**: complex sleep behaviours
- VELCADE (bortezomib)**: fatal if given intrathecally
- XGEVA (denosumab)**: risk of severe symptomatic hypocalcemia

Pictures & Colors Speak 1000 Words

COLOURS USED WITHIN THE CHARTS

Green shading usually indicates HERBAL/LIFESTYLE related
Blue shading usually indicates PEDIATRIC related
Purple script usually indicates TRADE NAMES
Yellow highlights CLINICAL DIFFERENCES, PRACTICE GAPS & COMMON ?s
Navy script usually indicates MAJOR TRIALS
Pink script usually indicates PREGNANCY & LACTATION related
Gray script usually indicates DISCONTINUED drug
Purple shading usually indicates OVERVIEW/GUIDELINE approach

COMMONLY USED ABBREVIATIONS

BP	Blood pressure
Bz	Benzodiazepine
CI	Contraindication
CV	Cardiovascular
DI	Drug interaction
Dx	Diagnosis/disease
HSR	Hypersensitivity rxn
LFT	Liver function tests
M	Monitoring
OD	Daily
OTC	Over the counter
P	Porphyria
QID	Four times daily
eGFR	Estimated glomerular filtration rate
g	Generic available
GI	Gastrointestinal
HA	Headache
HF	Heart failure
HR	Heart rate
HS	Bedtime
SE	Side effect
SCr	Serum creatinine
SJS	Stevens Johnson Sx
Sx	Syndrome/symptom
Sz	Seizure
TID	Three times daily
Tx	Treatment

RxFiles Online www.RxFiles.ca

- Newsletters, Q&As, Trial Summaries available to all.
- Updated charts available to those with subscription.
- Links / Program Information / References / Search Feature / Online Store / **iPad, iPhone, Android.**
- RxFiles *Email Notification* of new postings.

All Charts sizes (pocket, standard & oversized) are tabbed.

Link to order form: <http://www.rxfiles.ca/rxfiles/uploads/documents/1A-CHT-Book-ORDERFORM.pdf>



Editors: Brent Jensen, Loren Regier

SYMBOLS

	Canada (We are Canadian)		
X	Non-formulary in Saskatchewan		
	Exception Drug Status (EDS) in Saskatchewan (SK) (1-800-667-2549)		
	Not covered by NIHB (Non-Insured Health Benefits) http://www.hc-sc.gc.ca/fnihb/nihb/pharmacy/drugbenefitlist/index.htm		
	Prior approval required by NIHB . Coverage for eligible First Nations & Inuit (1-800-580-0950)		
	Covered by NIHB. Found on the OTC charts (pgs 94-97) & identified ONLY for those drugs which have SK Formulary restrictions such as EDS or non-formulary status .		
\$	Retail <i>Cost to Consumer</i> based on acquisition cost, markup & dispensing fee in Saskatchewan. Lowest generic price used where available.		
	Tablet is scored. Appears as superscript, e.g. 25 ^c mg tablet.		
	Tastes good		
	Concern if drug or herbal is given Pre-Op		
	Avoid if patient has soybean & peanut allergy		
	Male		Female
	Herbals: likely safe		Herbals: possibly safe
	Dose ↓ may be required for liver dysfunction		
	Dose ↓ required for renal dysfunction if 1) drug ≥ 75% renal excretion 2) toxic if accumulates 3) an active metabolite requiring dose adjustment. [CrCl <60ml/min]		

DRUGS IN PREGNANCY & LACTATION RISK CATEGORIES

PREGNANCY [P]	LACTATION [L]
Safe P	Safe L
<ul style="list-style-type: none"> Compatible in pregnancy 	<ul style="list-style-type: none"> Compatible in breastfeeding
Likely Safe P	Likely Safe L
<ul style="list-style-type: none"> No (limited) human data – probably compatible Compatible – maternal benefit >> embryo-fetal risk Human data suggest low risk 	<ul style="list-style-type: none"> No (limited) human data – probably compatible
Caution P	Caution L
<ul style="list-style-type: none"> Human, and or animal, data suggest risk P Potential risk in specific trimester(s), as indicated by 'x' P_x 	<ul style="list-style-type: none"> Hold/delay breastfeeding No (limited) human data – potential toxicity
Contraindicated P	Contraindicated L
<ul style="list-style-type: none"> Contraindicated in pregnancy P Contraindicated in specific trimester(s), as indicated by 'x' P_x 	<ul style="list-style-type: none"> Contraindicated in breastfeeding
Unknown for Pregnancy P and/or Lactation L	
<ul style="list-style-type: none"> No (limited) human data – no relevant animal data 	
Reference: <i>Drugs in Pregnancy and Lactation</i> . 9 th ed. Briggs GE, Freeman RK, Yaffe SJ, editors. Williams and Wilkins; Philadelphia, PA: 2011.	

What you'll see in the charts:
P = pregnancy L = lactation risk category
Colours correspond to risk categories outlined in this table. Example, warfarin:
P = contraindicated 1st trimester
L = compatible during lactation

